Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Faslodex survival data

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

AstraZeneca's breast cancer therapy Faslodex (fulvestrant) is not significantly different from the firm's Arimidex (anastrazole) in the first mature survival data available since approval. Median duration of survival was 27.4 months vs. 27.7 months, respectively. After a median follow-up of 27.2 months, 75% of Faslodex patients vs. 76% of Arimidex patients had died of any cause. The data, presented Dec. 5 at the San Antonio Breast Cancer Symposium, are based on two Phase III trials in a total of 851 postmenopausal women with advanced breast cancer with progression following antiestrogen treatment. AstraZeneca is currently enrolling patients in its 650-patient EFECT study (Evaluation of Faslodex vs. Exemestane Clinical Trial) to compare Faslodex to Pfizer's Aromasin in postmenopausal women with hormone receptor-positive metastatic breast cancer...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002424

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel